L. Smith
Keine laufenden Positionen mehr
Vermögen: 8 Mio $ am 30.04.2024
Karriereverlauf von L. Smith
Ehemalige bekannte Positionen von L. Smith
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SPRINGWORKS THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2017 | 15.12.2020 |
| Corporate Officer/Principal | 15.12.2020 | 31.01.2024 | |
Bamboo Therapeutics, Inc.
 Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | Corporate Officer/Principal | 01.06.2016 | 01.08.2017 |
| UNITED THERAPEUTICS CORPORATION | Corporate Officer/Principal | 01.12.2014 | 01.06.2016 |
Ausbildung von L. Smith
| University of New Hampshire | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SPRINGWORKS THERAPEUTICS, INC. | Health Technology |
| UNITED THERAPEUTICS CORPORATION | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Bamboo Therapeutics, Inc.
Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | Health Technology |
